Singapore Non-Small Cell Lung Cancer Diagnostics Market to 2032
Overview
The Singapore Non-Small Cell Lung Cancer Diagnostics Market is expected to reach a 8.13 USD Million by 2032 and is projected to grow at a CAGR of 25.33% from 2025 to 2032.
Revenue, 2024 (USD Million)
2.55
Forecast, 2032 (USD Million)
8.13
CAGR, 2024 - 2032
25.33%
Report Coverage
Singapore
Singapore Non-Small Cell Lung Cancer Diagnostics Market 2018-2032 USD Million
Singapore Non-Small Cell Lung Cancer Diagnostics Market, Key Findings (2025-2032)
Market Growth and Projections:
- Market Size (2024): 2.55 USD Million
- Projected Market Size (2032): 8.13 USD Million
- CAGR (2025-2032): 25.33%
Key Findings of Singapore Non-Small Cell Lung Cancer Diagnostics Market
- The Singapore Non-Small Cell Lung Cancer Diagnostics Market was valued at 2.55 USD Million in 2024.
- The Singapore Non-Small Cell Lung Cancer Diagnostics Market is likely to grow at a CAGR of 25.33% during the forecast period of 2024 to 2032.
- In 2024, the Largest segment Molecular Test in Test Segment accounted for the largest share of the market with a revenue of 1.35 USD Million
- The fastest growing segment Imaging Test in Test Segment grew Fastest with a CAGR of 28.85% during the forecast period from 2024 to 2032.
Singapore Non-Small Cell Lung Cancer Diagnostics Market Scope
Singapore Non-Small Cell Lung Cancer Diagnostics Market Segmentation & Scope
Product
- Services and Softwares
- Reagents and Kits
- Instruments
Test
- Thorecentesis
- Sputum Cytology
- Biopsy
- Immunohistochemistry
- Others
- Imaging Test
- Molecular Test
End User
- Institutes and Research Centers
- Academics
- Hospital
- Clinical Laboratories
Lung Cancer Type
- Others
- Large Cell Carcinoma
- Lung Squamous CellCarcinoma (LUSC)
- Lung Adenocarcinoma (LUAD)
Singapore Non-Small Cell Lung Cancer Diagnostics Market Data Coverage Insights
| Study Period | 2024-2032 |
| Base Year | 2020 |
| Unit | Revenue in USD Million |
| Market Value in 2024 | 2.55 USD Million |
| Market Value in 2032 | 8.13 USD Million |
| CAGR (2025-2032) | 25.33% |
| Historic Data | 2016-2023 |
| Market Segments Covered | Product,Test,End User,Lung Cancer Type |
Regional Insights:
-
Leading Market (2024-2032): Singapore, leading in terms of revenue 2.55 USD Million in 2024
- Key Country: Singapore, leading in terms of revenue with value of 2.55 USD Million in 2024.
Segments and Scope
-
Singapore Non-Small Cell Lung Cancer Diagnostics Market to 2032, By Product
- Instruments is the largest segment in Singapore Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a revenue of 1.14 USD Million in the year 2024.
- Reagents and Kits is the Fastest growing segment in Singapore Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a Growth rate of 24.83 % in forecast period 2025-2032.
-
Singapore Non-Small Cell Lung Cancer Diagnostics Market to 2032, By Test
- Molecular Test is the largest segment in Singapore Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a revenue of 1.35 USD Million in the year 2024.
- Imaging Test is the Fastest growing segment in Singapore Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a Growth rate of 25.36 % in forecast period 2025-2032.
-
Singapore Non-Small Cell Lung Cancer Diagnostics Market to 2032, By End User
- Clinical Laboratories is the largest segment in Singapore Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a revenue of 0.91 USD Million in the year 2024.
- Clinical Laboratories is the Fastest growing segment in Singapore Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a Growth rate of 26.88 % in forecast period 2025-2032.
-
Singapore Non-Small Cell Lung Cancer Diagnostics Market to 2032, By Lung Cancer Type
- Lung Adenocarcinoma (LUAD) is the largest segment in Singapore Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a revenue of 1.30 USD Million in the year 2024.
- Lung Adenocarcinoma (LUAD) is the Fastest growing segment in Singapore Non-Small Cell Lung Cancer Diagnostics Market to 2032 with a Growth rate of 25.81 % in forecast period 2025-2032.
Singapore Non-Small Cell Lung Cancer Diagnostics Market Company Share Analysis
| Company Name |
|
||
| QIAGEN | |||
| Quest Diagnostics Incorporated | |||
| Abbott | |||
| General Electric | |||
| F. Hoffmann-La Roche Ltd. | |||
Singapore Non-Small Cell Lung Cancer Diagnostics Market Geographical Sales Distribution, 2018-2032 USD Million
Singapore Non-Small Cell Lung Cancer Diagnostics Market Company Profiling
Industry Related Reports
Frequently Asked Questions
The Singapore Non-Small Cell Lung Cancer Diagnostics Market is segmented based on Segmentation Product,Test,End User,Lung Cancer Type.
Singapore Non-Small Cell Lung Cancer Diagnostics Market was valued at USD 2.55(Revenue in USD Million) in 2020.
Singapore Non-Small Cell Lung Cancer Diagnostics Market is projected to grow at a CAGR of 25.33% during the forecast period of 2024 to 2032.
The Molecular Test segment is expected to dominate the Singapore Non-Small Cell Lung Cancer Diagnostics Market, holding a largest market share of 1.35 USD Million in 2024
Singapore Non-Small Cell Lung Cancer Diagnostics Market Scope
Singapore Non-Small Cell Lung Cancer Diagnostics Market Segmentation & Scope
Product
- Services and Softwares
- Reagents and Kits
- Instruments
Test
- Thorecentesis
- Sputum Cytology
- Biopsy
- Immunohistochemistry
- Others
- Imaging Test
- Molecular Test
End User
- Institutes and Research Centers
- Academics
- Hospital
- Clinical Laboratories
Lung Cancer Type
- Others
- Large Cell Carcinoma
- Lung Squamous CellCarcinoma (LUSC)
- Lung Adenocarcinoma (LUAD)
Frequently Asked Questions
The Singapore Non-Small Cell Lung Cancer Diagnostics Market is segmented based on Segmentation Product,Test,End User,Lung Cancer Type.
Singapore Non-Small Cell Lung Cancer Diagnostics Market was valued at USD 2.55(Revenue in USD Million) in 2020.
Singapore Non-Small Cell Lung Cancer Diagnostics Market is projected to grow at a CAGR of 25.33% during the forecast period of 2024 to 2032.
The estimated market value of the Singapore Non-Small Cell Lung Cancer Diagnostics Market for final year is USD 8.13 (USD Million).
Singapore Non-Small Cell Lung Cancer Diagnostics Market Company Profiling
Frequently Asked Questions
The Singapore Non-Small Cell Lung Cancer Diagnostics Market is segmented based on Segmentation Product,Test,End User,Lung Cancer Type.
Singapore Non-Small Cell Lung Cancer Diagnostics Market was valued at USD 2.55(Revenue in USD Million) in 2020.
Singapore Non-Small Cell Lung Cancer Diagnostics Market is projected to grow at a CAGR of 25.33% during the forecast period of 2024 to 2032.
The estimated market value of the Singapore Non-Small Cell Lung Cancer Diagnostics Market for final year is USD 8.13 (USD Million).
HAVE A QUESTION?
Get expert advice on the right strategy for your business at no cost. We also offer customized subscription plans and affordable discounts for startups and universities.